HEMATOLOGICAL MALIGNANCIES: LEUKEMIAS, LYMPHOMAS AND MYELOMAS

VolverGo back

Resultados 75 results. LastUpdate Updated on 14/08/2022 [08:38:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Page1/3 nextPage   results/page


BIOMARKERS FOR FIMEPINOSTAT THERAPY

Publication No.: WO2022169731A1 11/08/2022

Applicant:

CURIS INC [US]

Absstract of: WO2022169731A1

The present invention provides biomarkers for identifying patients suffering from diffuse large B-cell lymphoma who are likely to respond to therapy with fimepinostat. The invention further provides methods for treating such patients with fimepinostat.

traducir

NAPHTHYL UREA COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF

Publication No.: WO2022166994A1 11/08/2022

Applicant:

HENAN RADIOMEDICAL SCIENCE AND TECH CO LTD [CN]

CN_112961120_A

Absstract of: WO2022166994A1

Provided in the present invention are a naphthyl urea compound, a preparation method therefor and the use thereof. A naphthyl urea parent nucleus group with a biological activity contained in the naphthyl urea compound is further chemically modified to generate a plurality of compounds with a higher biological activity, such that the wide uses thereof in biological medicine and the prospects for the development of pharmaceutical preparations of such compounds are expanded. The compounds at a low dose (sub-micromolar) can significantly inhibit the proliferation of liver cancer cells, breast cancer cells, lung cancer cells, drug-resistant lung cancer cells, leukemia cells etc., can induce cell cycle arrest at a G2/M phase, and can promote cell apoptosis, which indicates that the compounds could prospectively be developed into an anti-tumor drug.

traducir

PIM KINASE INHIBITOR

Publication No.: WO2022166860A1 11/08/2022

Applicant:

HANGZHOU BANGSHUN PHARMACEUTICAL CO LTD [CN]

CN_114409656_PA

Absstract of: WO2022166860A1

A compound having a structure as shown in general formula (I), a deuterated compound, a stereoisomer, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same, and use thereof. The compound has a good PIM kinase inhibitory effect, is a novel and ideal PIM inhibitor having high activity and low toxicity, and can be used for treating and/or preventing hematoma such as acute myeloid leukemia, bone marrow fibrosis and chronic lymphocytic leukemia, solid tumors such as gastric cancer and prostate cancer, and other diseases.

traducir

USE OF PPAR-DELTA INHIBITOR IN COMBINATION WITH IMMUNOTHERAPEUTIC DRUG FOR PREPARING ANTI-TUMOR DRUG

Publication No.: WO2022166909A1 11/08/2022

Applicant:

FIRST HOSPITAL JILIN UNIV [CN]

CN_112972688_A

Absstract of: WO2022166909A1

It relates to a pharmaceutical use of a PPARδ inhibitor in combination with an immunotherapeutic drug for preparing an anti-tumor drug, wherein the immunotherapeutic drug is an immune agonist or an immune checkpoint inhibitor, the tumor is preferably melanoma, mammary cancer, ovarian cancer, pancreatic cancer, lung cancer, liver cancer, esophageal cancer, colorectal cancer, colonic cancer, lymphoma, brain tumor, sarcoma, cervical cancer, prostate cancer, bladder cancer, osteosarcoma, head and neck cancers, renal cell carcinoma, or stomach cancer. The medicine exhibits significant anti-cancer effect, strong targeting ability which has little side effect.

traducir

METHODS OF TUMOR VACCINATION

Publication No.: US2022249639A1 11/08/2022

Applicant:

DCPRIME B V [NL]

WO_2022157715_A1

Absstract of: US2022249639A1

Provided herein are methods for treating a tumor or generating an immune response against a tumor in a subject in need, including one or more intratumoral administration steps each comprising administering to the subject at a tumor site, an effective amount of a first composition, and one or more vaccination steps each comprising administering to the subject at a site distal to the tumor site, an effective amount of a second composition. The first and second composition may each comprise an allogeneic leukemia-derived cell that is useful in eliciting an immune response against the tumor.

traducir

ANTIGEN BINDING MOLECULES AND METHODS THEREOF II

Publication No.: WO2022169416A1 11/08/2022

Applicant:

AGENCY SCIENCE TECH & RES [SG]

Absstract of: WO2022169416A1

The invention relates to antigen-binding molecules that specifically bind to MHC Class I DLA-12 antigen. In one embodiment, the antigen-binding molecule is an antibody that specifically binds to canine MHC Class I DLA-12 antigen. Chimeric molecules of the antibody conjugated to another heterologous moiety are also provided. In one embodiment, the heterologous moiety is monomethyl auristatin E (MMAE). A method of inhibiting cancer using the antibody or the chimeric molecule thereof is also provided. In another embodiment, the antibody-MMAE conjugate suppresses tumour development in a murine model of B cell lymphoma.

traducir

Low dose antibody-based methods for treating hematologic malignancies

Publication No.: US2022251196A1 11/08/2022

Applicant:

ACTINIUM PHAMACEUTICALS INC [US]

JP_2022090047_A

Absstract of: US2022251196A1

This invention provides a method for treating a subject afflicted with a hematologic malignancy comprising administering to the subject an agent targeting a hematologic malignancy-associated antigen, wherein the subject has a low peripheral cancerous cell burden. This invention also provides a method for treating a subject afflicted with a hematologic malignancy and having a high peripheral cancerous cell burden, comprising (i) medically lowering the subject's peripheral cancerous cell burden, and (ii) while the subject's peripheral cancerous cell burden is still low, administering to the subject an agent targeting a hematologic malignancy-associated antigen. Particularly envisioned are the subject methods for treating acute myeloid leukemia using an anti-CD33 antibody labeled with an alpha-emitting isotope, such as 225Ac-HuM195.

traducir

ANTIBODIES HAVING SPECIFICITY FOR CD38 AND USES THEREOF

Publication No.: US2022251234A1 11/08/2022

Applicant:

INST NAT SANTE RECH MED [FR]
UNIV PARIS [FR]

KR_20220034807_PA

Absstract of: US2022251234A1

CD38 is also expressed in a variety of malignant hematological diseases, including multiple myeloma. In the present invention, the inventors have generated a new antibody against CD38 that could be suitable for producing bispecific antibodies as well as CAR-T cells. In particular, the inventors report the development of Bi38-3, a new bispecific T cell engager that targeted CD38 on MM cells and recruited cytotoxic T cells through the CD3ε. Bi38-3 lacked the Fc region of natural mAb, which contributes to resistance processes, but triggered T cells to proliferate, release cytokine and lyse CD38 positive MM cells in vitro. Similarly, Bi38-3 induced autologous T cells to eliminate tumor plasma cells isolated from MM patients both at diagnosis and at relapse. The cytotoxicity triggered by Bi38-3 was restricted to cells expressing high levels of CD38 and preserved the integrity of T, B and NK lymphocytes in vitro. Importantly, Bi38-3 rapidly reduced tumor cells in an MM1.S xenograft mouse model of human MM. Taken together, the results show that the antibody of the present invention is an effective reagent to specifically eliminate CD38 positive malignant cells without significantly affecting CD38 lowly expressing cells and represents a promising novel immunotherapeutic tool for the treatment of malignant hematological diseases, and especially multiple myeloma.

traducir

MONOCLONAL ANTIBODIES AND METHODS OF USE

Publication No.: US2022251230A1 11/08/2022

Applicant:

ELANCO TIERGESUNDHEIT AG [US]

EP_3378489_A1

Absstract of: US2022251230A1

This disclosure relates to immunogens and monoclonal antibodies useful in the identification and/or treatment of cancer cells, including those of the dog. In one example, chimeric anti-canine CD20 antibodies are provided. The antibodies can be used therapeutically to treat lymphoma in dogs.

traducir

Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof

Publication No.: US2022249568A1 11/08/2022

Applicant:

CELLULAR BIOMEDICINE GROUP HK LTD [CN]

US_2022031752_A1

Absstract of: US2022249568A1

The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B-cell lymphoma, leukemia and other diseases.

traducir

CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS TARGETING ALK

Publication No.: US2022249561A1 11/08/2022

Applicant:

UNIV SHINSHU [JP]

EP_3978611_A1

Absstract of: US2022249561A1

The present invention is intended to develop a chimeric antigen receptor (CAR) that is effective against solid tumor expressing anaplastic lymphoma kinase (ALK). The present invention provides a polynucleotide encoding a CAR protein comprising a target binding domain binding to an extracellular ligand binding region of ALK, a transmembrane domain, and an intracellular signaling domain. The target binding domain of the polynucleotide is selected from among FAM150A, FAM150B, and fragments thereof binding to the extracellular ligand binding region of ALK. The present invention also provides a genetically modified cell comprising the polynucleotide introduced thereinto.

traducir

AZACITIDINE IN COMBINATION WITH VENETOCLAX, GILTERITINIB, MIDOSTAURIN OR OTHER COMPOUNDS FOR TREATING LEUKEMIA OR MYELODYSPLASTIC SYNDROME

Publication No.: US2022249528A1 11/08/2022

Applicant:

CELGENE CORP [US]

US_2022249529_A1

Absstract of: US2022249528A1

Provided herein are methods for using 5-azacytidine in combination with one or more additional agents to treat diseases and disorders including acute myeloid or myelogenous leukemia (AML). Other disease and disorders those associated with abnormal cell proliferation, myelodysplastic syndromes (MDS), abnormal cell proliferation, hematologic disorders, and immune disorders, among others.

traducir

AZACITIDINE IN COMBINATION WITH VENETOCLAX, GILTERITINIB, MIDOSTAURIN OR OTHER COMPOUNDS FOR TREATING LEUKEMIA OR MYELODYSPLASTIC SYNDROME

Publication No.: US2022249529A1 11/08/2022

Applicant:

CELGENE QUANTICEL RES INC [US]

US_2022249528_A1

Absstract of: US2022249529A1

Provided herein are methods for using 5-azacytidine in combination with additional agents to treat diseases and disorders including AML.

traducir

PLANT VIRUS PARTICLES FOR DELIVERY OF ANTIMITOTIC AGENTS

Publication No.: US2022249688A1 11/08/2022

Applicant:

UNIV CASE WESTERN RESERVE [US]

US_2021008222_A1

Absstract of: US2022249688A1

Anti-lymphoma plant virus particles are described. The anti-lymphoma plant virus particles include a filamentous or rod-shaped plant virus particle linked to an antimitotic agent. A therapeutically effective amount of an anti-lymphoma plant virus particle can be administered to a subject to provide a method of treating lymphoma.

traducir

Combination comprising a TIM-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia

Publication No.: AU2021207348A1 11/08/2022

Applicant:

NOVARTIS AG

TW_202140037_PA

Absstract of: AU2021207348A1

Combination therapies comprising TIM-3 inhibitors are disclosed. The combinations can be used to treat cancerous conditions and disorders, including hematologic cancers.

traducir

CCR4 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CCR4 POSITIVE MALIGNANCIES

Publication No.: US2022249560A1 11/08/2022

Applicant:

HOPE CITY [US]

JP_2022533247_A

Absstract of: US2022249560A1

Chimeric antigen receptors for use in treating lymphoma-associated C-C chemokine receptor type 4 (CCR4) and other cancers expressing CCR4 are described.

traducir

ENHANCED HYBRIDOMA GENERATION

Publication No.: WO2022170074A1 11/08/2022

Applicant:

AMGEN INC [US]

Absstract of: WO2022170074A1

Provided herein are methods of generating hybridomas and related methods of producing antigen-specific antibodies. In exemplary embodiments, the method comprises (a) preparing an enriched population of IgG-positive (IgG+) memory B cells from cells obtained from secondary lymphoid organs of one or more immunized non-human animals, wherein (i) less than or about 10% of the enriched population are IgM-positive (IgM+) B cells and/or (ii) the ratio of the IgG+ memory B cell count to IgM+ B cell count of the enriched population is greater than about 0.5, optionally, greater than about 1 or greater than about 2, (b) bulk-culturing the enriched population to obtain an expanded population; and (c) fusing cells of the expanded population with myeloma cells to obtain hybridomas. In exemplary aspects, the hybridomas obtained represent at least 10% or at least 15% of the IgG+ memory B cell repertoire produced by the immunized animals.

traducir

PEPTIDASE ENHANCED CYTOTOXIC DIPEPTIDES

Publication No.: WO2022167087A1 11/08/2022

Applicant:

ONCOPEPTIDES AB [SE]

Absstract of: WO2022167087A1

The invention provides compounds of formula (I), that are peptidase enhanced cytotoxics. The invention further provides pharmaceutical compositions comprising the compounds, and the use of the compounds or pharmaceutical compositions as a medicament, particularly for use in the treatment or prophylaxis of cancers such as multiple myeloma, osteosarcoma, breast cancer, lung cancer, ovarian cancer, leukaemia and lymphoma.

traducir

ANTIGEN BINDING MOLECULES AND METHODS THEREOF I

Publication No.: WO2022169415A1 11/08/2022

Applicant:

AGENCY SCIENCE TECH & RES [SG]

Absstract of: WO2022169415A1

The invention relates to antigen-binding molecules that specifically bind to IgM p-chain antigen. In one embodiment, the antigen-binding molecule is an antibody that specifically binds to canine IgM p-chain antigen. Chimeric molecules of the antibody conjugated to another heterologous moiety are also provided. In one embodiment, the heterologous moiety is monomethyl auristatin E (MMAE). A method of inhibiting cancer using the antibody or the chimeric molecule thereof is also provided. In another embodiment, the antibody-MMAE conjugate suppresses tumour development in a murine model of B cell lymphoma.

traducir

METHODS FOR THE TREATMENT OF ADULT T-CELL LEUKEMIA/LYMPHOMA

Publication No.: EP4037774A1 10/08/2022

Applicant:

INST NAT SANTE RECH MED [FR]
CENTRE NAT RECH SCIENT [FR]
ASSIST PUBLIQUE HOPITAUX PARIS APHP [FR]
UNIV PARIS CITE [FR]

WO_2021064069_A1

Absstract of: WO2021064069A1

Adult T-cell leukemia/lymphoma (ATL) is an aggressive proliferation of mature activated CD4+ T cells associated with the human T-cell lymphotropic virus type I (HTLV-I). The inventors performed an integrated genomic analysis of a retrospective cohort of 62 ATL patients mainly originating from Africa and the Caribbean area. In particular, they identified a subset of mutations in the TCR/NF-KB pathway (PLCG1, CARD11, PRKCB, CBLB, IRF4, CSNK1A1, FYN, RHOA, VAV1). Furthermore, the inventors investigated the effects of an anti-CD3 antibody (OKT3) exposure on 4 ATL samples including 2 cases harboring CARD 11 and PRKCB gain of function alterations and 2 cases without any TCR pathway mutation. The data suggest that ATL harboring TCR pathway mutations clearly responded to anti-CD3 (Fig. IB, red + OKT3) and died by apoptosis possibly by a mechanism resembling AICD. Importantly, these TCR-pathway/NFKB mutated patients also showed poorer outcome as compared to unmutated cases. Accordingly, the present invention relates to a method of treating adult T-cell leukemia/lymphoma (ATL) in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an anti-CD3 antibody.

traducir

COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND DASATINIB OR NILOTINIB FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA

Publication No.: EP4039256A1 10/08/2022

Applicant:

AMGEN INC [US]

ES_2916721_T3

Absstract of: EP4039256A1

The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.

traducir

VACCINE COMPOSITIONS FOR TREATMENT OF ZIKA VIRUS

Publication No.: EP4039272A1 10/08/2022

Applicant:

VARIATION BIOTECHNOLOGIES INC [CA]

MX_2019000725_A

Absstract of: EP4039272A1

The present disclosure provides compositions and methods useful for preventing and treating Zika virus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more Zika epitopes, such as, for example, from Zika envelope glycoprotein E and the Zika structural protein NS1 including variants thereof.

traducir

Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy

Publication No.: AU2021209940A1 04/08/2022

Applicant:

JUNO THERAPEUTICS INC

WO_2021151008_A1

Absstract of: AU2021209940A1

Provided herein are methods of administering a dose of T cells for treating subjects with indolent non-Hodgkin's lymphoma (NHL), and related methods, compositions, uses and articles of manufacture. The cells express a recombinant receptor such as a chimeric antigen receptor (CAR) for targeting an antigen of the lymphoma, such as CD19. In some embodiments, the methods are for treating grade 1-3 A follicular lymphoma (FL 1-3 A) or marginal zone lymphoma (MZL), including in heavily pretreated or poor-prognosis subjects, such as subjects that have relapsed after treatment with, or are refractory to treatment with, one or more prior therapies.

traducir

Substituted straight chain spiro derivatives

Publication No.: AU2020404305A1 04/08/2022

Applicant:

JANSSEN PHARMACEUTICA NV

CN_114867721_PA

Absstract of: AU2020404305A1

Provided herein are pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN); and diabetes.

traducir

ANTI-CD19 THERAPY IN PATIENTS HAVING A LIMITED NUMBER OF NK CELLS

Nº publicación: US2022242952A1 04/08/2022

Applicant:

MORPHOSYS AG [DE]

JP_2022532519_A

Absstract of: US2022242952A1

The present disclosure provides characteristics and biomarkers in patients that benefit from treatment with anti-CD19 antibodies (MOR00208, XmAb5574). Furthermore, the present application relates to anti-CD19 antibodies for the treatment of leukemia or lymphoma in patients having a peripheral NK cell count at baseline of less or equal to 100 NK cells/μl

traducir

Page1/3 nextPage results/page

punteroimgGo back